Diana Gernhardt

560 total citations
8 papers, 338 citations indexed

About

Diana Gernhardt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Diana Gernhardt has authored 8 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 2 papers in Surgery. Recurrent topics in Diana Gernhardt's work include Colorectal Cancer Treatments and Studies (7 papers), Lung Cancer Treatments and Mutations (5 papers) and HER2/EGFR in Cancer Research (3 papers). Diana Gernhardt is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Lung Cancer Treatments and Mutations (5 papers) and HER2/EGFR in Cancer Research (3 papers). Diana Gernhardt collaborates with scholars based in United States, Australia and Spain. Diana Gernhardt's co-authors include Joseph O’Connell, Ian W. Taylor, Nagdeep Giri, Stephen P. Letrent, Alicyn Campbell, Karen L. Reckamp, Marianna Koczywas, D. Ross Camidge, Jane Liang and Pasi A. Jänne and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Diana Gernhardt

8 papers receiving 334 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Diana Gernhardt United States	7	248	200	135	56	24	8	338
J.C.-H. Yang Taiwan	5	263 1.1×	281 1.4×	94 0.7×	46 0.8×	12 0.5×	12	353
JG Kuiper Netherlands	6	233 0.9×	287 1.4×	80 0.6×	87 1.6×	15 0.6×	9	331
Kaoru Irisa Japan	9	214 0.9×	236 1.2×	76 0.6×	48 0.9×	10 0.4×	16	333
Amandine Quivy France	6	214 0.9×	121 0.6×	83 0.6×	34 0.6×	19 0.8×	9	351
Joo‐Hang Kim South Korea	10	310 1.3×	338 1.7×	109 0.8×	66 1.2×	14 0.6×	17	445
Guilherme Harada Brazil	11	155 0.6×	161 0.8×	90 0.7×	66 1.2×	15 0.6×	40	317
Masayuki Yasugi Japan	9	240 1.0×	241 1.2×	132 1.0×	48 0.9×	12 0.5×	22	358
L. Paz-Ares Spain	9	291 1.2×	215 1.1×	97 0.7×	40 0.7×	13 0.5×	51	374
Susan E. Jorge Brazil	7	137 0.6×	200 1.0×	112 0.8×	51 0.9×	15 0.6×	22	303

Countries citing papers authored by Diana Gernhardt

Since Specialization

Citations

This map shows the geographic impact of Diana Gernhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana Gernhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana Gernhardt more than expected).

Fields of papers citing papers by Diana Gernhardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana Gernhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana Gernhardt. The network helps show where Diana Gernhardt may publish in the future.

Co-authorship network of co-authors of Diana Gernhardt

This figure shows the co-authorship network connecting the top 25 collaborators of Diana Gernhardt. A scholar is included among the top collaborators of Diana Gernhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana Gernhardt. Diana Gernhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Zhou, Qing, Yi‐Long Wu, J. Corral, et al.. (2019). Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis. Future Oncology. 15(13). 1481–1491. 12 indexed citations

Kim, Dong‐Wan, Edward B. Garon, Aminah Jatoi, et al.. (2017). Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung Cancer. 106. 76–82. 12 indexed citations

Calvo, Emiliano, Jean‐Charles Soria, Wen Wee, et al.. (2016). A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. Clinical Cancer Research. 23(5). 1177–1185. 29 indexed citations

Lacouture, Mario E., Dorothy Keefe, Stephen T. Sonis, et al.. (2016). A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Annals of Oncology. 27(9). 1712–1718. 49 indexed citations

Lacouture, Mario E., Stephen T. Sonis, Nagdeep Giri, et al.. (2015). Prophylactic doxycycline (doxy) lessens rash from dacomitinib (D) an EGFR inhibitor with no rash or diarrhea improvement from corticosteroids or probiotics.. Journal of Clinical Oncology. 33(15_suppl). e19049–e19049. 2 indexed citations

Reckamp, Karen L., Giuseppe Giaccone, D. Ross Camidge, et al.. (2014). A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. 120(8). 1145–1154. 120 indexed citations

Park, Keunchil, Byoung Chul Cho, Dong‐Wan Kim, et al.. (2014). Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial. Journal of Thoracic Oncology. 9(10). 1523–1531. 20 indexed citations

Robert, Nicholas J., Mansoor N. Saleh, Devchand Paul, et al.. (2011). Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial. Clinical Breast Cancer. 11(2). 82–92. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact